Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04749238
Other study ID # Nucleo 514/2020
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 26, 2021
Est. completion date October 24, 2021

Study information

Verified date December 2022
Source Santersus AG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This open non-randomized controlled single center study investigates to what extent the removal of circulating Neutrophil Extracellular Traps (NETs) from blood by NucleoCapture device has a positive effect on the treatment of patients with sepsis and sepsis-associated AKI (SA-AKI).


Description:

The term "sepsis" refers to a clinical syndrome in which a dysregulation of the host's inflammatory reaction to infection leads to a life-threatening of organ dysfunctions. Sepsis and septic shock are major causes of death in intensive care units worldwide. Sepsis remains the most important cause of AKI in the intensive care unit (ICU) with 15%-20% of patients with sepsis-associated AKI (SA-AKI) prescribed RRT . In addition to association with short term mortality, AKI is also linked to the later development of CKD, ESRD, and long-term increased risk of death NETosis is a unique form of neutrophil cell death that is characterized by the release of neutrophil extracellular traps (NETs) composed of DNA web-like structures decorated with highly cytotoxic protein components. Release of NETs leads to bystander tissue damage (including the kidneys) and drives a fatal course of disease in sepsis patients. The plasmapheresis is a medical procedure, where pathogenic components are being removed from the blood by adsorbers outside the body in an extracorporeal circulation. For removal of the pathogenic substances the plasma is separated from the blood to pass the adsorber. The purified plasma is merged with the solid blood components thereafter and returned to the patient. The NucleoCapture device provide highly selective removal of neutrophil extracellular traps from human blood during plasmapheresis procedure.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date October 24, 2021
Est. primary completion date October 24, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Male or female = 18 and = 75 years of age. - Meet the clinical criteria of sepsis according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)) - Written informed consent Exclusion Criteria: - A terminal state - Active bleeding or uncontrolled acute massive bleeding

Study Design


Related Conditions & MeSH terms


Intervention

Device:
NucleoCapture device
Device: 100 ml NucleoCapture selective DNA adsorber. Treatment with NucleoCapture in one arm

Locations

Country Name City State
Russian Federation North-Western Regional Scientific and Clinical Center named after L.G. Sokolov Saint- Petersburg

Sponsors (1)

Lead Sponsor Collaborator
Santersus AG

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Other Blood level of neutrophil extracellular traps (NETs) change over time Change of NETs in blood over time for each patient and in average in group from [start of treatment] through 28 days after
Primary Incidence of acute kidney injury (AKI) Incidence of acute kidney injury (AKI) in accordance with Kidney Disease Improving Global Outcomes (KDIGO) definitions for AKI from [start of treatment] through 28 days after
Primary Severity of acute kidney injury (AKI) Severity of acute kidney injury (AKI) in accordance with KDIGO definitions for AKI from [start of treatment] through 28 days after
Primary Rate of AKI transition to the more severe stage (for patients with AKI at baseline). Rate of worsening of acute kidney injury (AKI) in accordance with KDIGO AKI classification (Changing stages from 1 to 2, from 2 to 3). from [start of treatment] through 28 days after
Primary Serum creatinine change over time Change of creatinine in serum over time for each patient and in average in group from [start of treatment] through 28 days after
Primary Serum urea change over time Change of urea in serum over time for each patient and in average in group from [start of treatment] through 28 days after
Primary Urine output change Change of urine output over time for each patient and in average in group from [start of treatment] through 28 days after
Secondary All-cause mortality Mortality for any reasons for each patient and in average in group from [start of treatment] through 28 days after
Secondary SOFA scores change Change in SOFA scores over time for each patient and in average in group from [start of treatment] through 28 days after
Secondary qSOFA scores change Change in qSOFA scores over time for each patient and in average in group from [start of treatment] through 28 days after
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3